New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Laura Helbling
Laura Helbling is Director of Research at Prevision Policy and a Senior Writer at The RPM Report (now Pink Sheet). Laura has a degree in magazine journalism from the University of Missouri School of Journalism.
Advertisement
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Laura Helbling
More US FDA Departures: ODE II Director Rosebraugh, GI Division Director Griebel to Retire
FDA will have three leadership positions vacant in the Office of Drug Evaluation II when Curtis Rosebraugh leaves at the end of the month.
It's NTAP Season!
In a Pink Sheet podcast, Prevision Policy analysts discuss the US Medicare program's new technology add-on payment process.
US FDA Pushes Back On Proposal For Early Clinical Designations To Support Higher Reimbursement Decisions
Breakthrough, RMAT designations signal clinical potential and are not intended to have reimbursement impact after approval, FDA says.
Reimbursement Challenge: CMS Questions Azedra Endpoint While Still Under FDA Review
Progenics' radiopharmaceutical using novel surrogate endpoint for US FDA review; CMS seems unimpressed, which doesn't bode well for new technology add-on payment.
Liposomal Drugs Should Not Be Compounded – Until Technology Catches Up
US FDA’s Pharmacy Compounding Advisory Committee agrees with AbbVie that liposomal drugs and products using hot melt extrusion should be listed as prohibited from compounding – but the panel also hopes to see technology advance to change that conclusion.
FDA Endocrinology Division To Be Led By Thanh Hai On Interim Basis; Guettier Leaving For Private Sector
Mary Thanh Hai ran the US agency's division for seven years before moving up in 2013; Guettier’s departure may provide an opportunity for CDER Director Woodcock to start to implement her vision for changes in the Office of New Drugs.
Advertisement